Brian Marckx, CFA
Long/short equity

CombiMatrix Exploiting Growth Of Chromosomal Microarray For Prenatal Analysis


CombiMatrix Corporation (NASDAQ:CBMX), founded in 1995 and currently headquartered in Irvine, CA, is involved in the field of molecular diagnostics with a primary focus on prenatal and postnatal genetic testing, miscarriage/stillbirth management and the diagnosis of developmental disorders (and to a lesser extent hematology/oncology genetic testing). The company performs a variety of methods of genetic testing out of its CLIA and CAP-certified lab including chromosomal microarray analysis (CMA).

While the company also offers other types of genetic tests for areas outside of prenatal disorders, including fluorescence in situ hybridization (FISH) for genetic abnormalities associated with cancer and hematological diseases, and traditional karyotyping, CBMX has recently shifted the majority of its focus for growth on CMA in the

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details